Achaogen, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: South San Francisco CA United States (2002)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2009
NCT00822978
First Marketed Drug
2018
plazomicin sulfate (zemdri)
First NDA Approval
2018
plazomicin sulfate (zemdri)
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Achaogen, Inc. | ACHAOGEN INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Infections (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pyelonephritis (Phase 3)

Renal Insufficiency (Phase 1)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 10